Chief commercial officer Hopman sells $7,015 of Beta Bionics stock

Chief Commercial Officer Mark Hopman of Beta Bionics Inc. (NASDAQ: BBNX) sold 370 shares of the company's common stock on October 1, 2026, as part of a pre-approved trading plan. The sale amounted to $7,015, with shares exchanged at prices between $18.96 and $19.9599. This transaction reduced Mr. Hopman's direct ownership of Beta Bionics stock to 56,109 shares.

Despite the sale, Beta Bionics stock remains below its transaction prices, having increased by nearly 99% over the past six months. The stock is currently trading at $17.63, which analysts consider overvalued, placing it on InvestingPro's Most Overvalued list. Beta Bionics has experienced a 52.5% revenue growth, but analysts remain skeptical about achieving profitability this year.

The company has received FDA clearance for its Mint patch pump, a device that syncs with continuous glucose monitors and can be controlled via smartphone. This development has garnered attention from financial analysts, with Wells Fargo and UBS raising their price targets for Beta Bionics. However, Beta Bionics has also announced a $125 million common stock offering, which may impact its share price.